Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

Abstract

We report the initial toxicity profile of a BCMA-directed cellular immunotherapy for patients with relapsed or refractory multiple myeloma. Antitumor activity was documented. (Funded by Bluebird Bio and Celgene; CRB-401 ClinicalTrials.gov number, NCT02658929.).

Keywords

Chimeric antigen receptorCAR T-cell therapyMultiple myelomaCancer researchMedicineAntigenCell therapyRefractory (planetary science)OncologyImmunologyCellT cellBiologyImmune systemGenetics

MeSH Terms

AdultAgedB-Cell Maturation AntigenCD4-CD8 RatioFemaleHumansImmunotherapyAdoptiveInfusionsIntravenousMaleMiddle AgedMultiple MyelomaProgression-Free SurvivalReceptorsChimeric AntigenT-Lymphocytes

Affiliated Institutions

Related Publications

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster , Michael Bishop , Constantine S. Tam +21 more

In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use o...

2018 New England Journal of Medicine 3775 citations

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian , F. Stephen Hodi , Julie R. Brahmer +27 more

Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse...

2012 New England Journal of Medicine 12335 citations

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

F. Stephen Hodi , Steven O’Day , David F. McDermott +26 more

Ipilimumab, with or without a gp100 peptide vaccine, as compared with gp100 alone, improved overall survival in patients with previously treated metastatic melanoma. Adverse eve...

2010 New England Journal of Medicine 14794 citations

Publication Info

Year: 2019
Type: article
Volume: 380
Issue: 18
Pages: 1726-1737
Citations: 1641
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1641

OpenAlex

Influential

1461

CrossRef

Cite This

APA Style

                            
                                
                                    Noopur Raje, 
                                
                                    Jesús G. Berdeja, 
                                
                                    Yi Lin
                                
                                et al.
                            
                            (2019). 
                            Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. 
                            New England Journal of Medicine
                            , 380
                            (18)
                            , 1726-1737.
                            https://doi.org/10.1056/nejmoa1817226
                        

Identifiers

DOI: 10.1056/nejmoa1817226
PMID: 31042825
PMCID: PMC8202968

Data Quality

Data completeness: 90%